Interpace Biosciences, Inc. is offering 3,100,000 shares of common stock in a firm-commitment underwritten offering, with a preliminary public price range of $6.00 to $7.00 per share.
At the assumed $6.50 price, Interpace estimates net proceeds of approximately $17.9 million, or approximately $20.8 million if the underwriters exercise their option for up to 465,000 additional shares in full. The offering’s closing is contingent on conditional Nasdaq listing approval; Interpace says it will not consummate the offering if its listing application is not approved. Proceeds are intended for working capital, capital expenditures and general corporate purposes, with possible use for test development or complementary investments. At $6.50, the company estimates immediate dilution of $2.03 per share to new investors.
Interpace sells molecular diagnostic tests focused on thyroid cancer after Medicare reimbursement ended for its PancraGEN pancreatic test and it stopped accepting specimens for that test. Thyroid-only pro forma revenue was $34.8 million in 2025 versus $20.3 million in 2022; adjusted EBITDA was $4.4 million versus a $4.9 million loss. A new pancreatic cyst test is in development, with analytical validation underway and clinical validation and utility studies planned across 2026 and 2027.
Interpace Biosciences expects preliminary, unaudited revenue of $10.1 million to $10.4 million for the third quarter ended September 30, 2026. The company said the range represents expected growth of approximately 11% to 14% from second-quarter 2026 revenue of $9.1 million and approximately 15% to 18% from third-quarter 2025 revenue of $8.8 million.
The estimate is based on information currently available to management, has not been reviewed by the company’s independent registered public accounting firm, and remains subject to completion of quarter-end closing procedures and review. Actual results may differ, including materially.
Interpace Biosciences, Inc. (IDXG) proposes a firm-commitment underwritten offering of 3,100,000 shares of common stock. The estimated price range is $6.00 to $7.00 per share, with final pricing to be set with the underwriter. A 30-day option permits the underwriter to buy up to 465,000 additional shares to cover over-allotments.
At an assumed $6.50 per share, Interpace estimates net proceeds of approximately $17.9 million, or $20.8 million if the option is fully exercised. It plans to use proceeds for working capital, capital expenditures and general corporate purposes; some may support development of pancreatic cyst and Barrett’s Esophagus tests or investments in complementary businesses, technologies, products or assets. Closing is contingent on conditional Nasdaq listing approval; if the application is not approved, Interpace will not complete the offering.
Interpace focuses on its ThyGeNEXT and ThyraMIRv2 thyroid tests after discontinuing PancraGEN following loss of Medicare reimbursement. Its thyroid-only pro forma results report 2025 revenue of $34.8 million and adjusted EBITDA of $4.4 million, excluding PancraGEN revenue and related costs. At the assumed price, the company estimates immediate net tangible book value dilution of $2.03 per share for purchasers.
Interpace Biosciences, Inc. (IDXG) is offering $20,000,000 of common stock in a firm commitment underwritten offering. It estimates net proceeds of approximately $17.8 million, or approximately $20.6 million if the underwriter exercises its 30-day option to purchase up to an additional $3,000,000 of common stock solely to cover over-allotments.
The company intends to use proceeds for working capital, capital expenditures and general corporate purposes; it may also use a portion for developing pancreatic cyst and Barrett’s Esophagus tests or investing in complementary businesses, technologies, products or assets. Closing is contingent on conditional Nasdaq listing approval; if its application is not approved, the company says it will not consummate the offering. The public offering price will be set at pricing. The $6.47 last reported OTCID sale price on September 22, 2026, is used as the assumed price in the company’s estimate of $2.01 per-share dilution to purchasers. A 1-for-5 reverse split took effect August 27, 2026. Thyroid-only pro forma revenue, excluding PancraGEN, was $34.8 million in 2025; the company reports a 19.7% CAGR from 2022 through 2025.
INTERPACE BIOSCIENCES, INC. (IDXG) approved and is implementing a 1-for-5 reverse stock split of its common stock. Stockholders authorized the board on August 20, 2026 to choose a ratio between 1:2 and 1:10, and the board set the final ratio at 1-for-5.
The reverse split becomes effective at 12:01 a.m. Eastern Time on August 27, 2026, when every five shares of common stock will be combined into one share, with no change to the $0.01 par value. Approximately 27.7 million shares outstanding will become approximately 5.5 million, while authorized shares remain unchanged, increasing potential headroom.
Fractional shares will not be issued and will instead be rounded up to the nearest whole share. The stock is expected to begin trading on a split-adjusted basis on OTCID on August 27, 2026, temporarily under ticker IDXGD for 20 trading days, with a new CUSIP of 46062X402. The company states the reverse split is primarily intended to help meet Nasdaq Capital Market minimum bid price requirements for a proposed uplisting.
Interpace Biosciences, Inc. (IDXG) filed an amended current report to document stockholder approval and adoption of its new 2026 Benefit Plans. At the August 20, 2026 annual meeting, stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.
The 2026 Equity Incentive Plan replaces the company’s 2019 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan replaces the 2019 Employee Stock Purchase Plan, as amended. No further equity awards will be granted under the 2019 Equity Incentive Plan and no further purchases will occur under the 2019 ESPP. Detailed terms of the new plans are provided in the company’s July 7, 2026 definitive proxy statement and in plan forms incorporated by reference as exhibits.
INTERPACE BIOSCIENCES, INC. (IDXG) reported the results of its 2026 annual meeting of stockholders held on August 20, 2026. Stockholders approved all matters submitted to a vote, including the election of directors and several additional proposals.
Directors Vijay Aggarwal, Thomas W. Burnell, Joseph D. Keegan, Ph.D., Fortunato Ron Rocca, and Stephen J. Sullivan each received over 24.4 million votes in favor, with no votes against and between 135,575 and 808,652 votes withheld, plus 1,347,136 broker non-votes for each nominee.
INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation and related share movements for CEO, President & Chairman Thomas W. Burnell. On August 20, 2026 he was granted 1,966,763 Restricted Stock Units (RSUs), each representing one share of common stock, all of which vested upon grant and included additional RSUs intended to cover tax obligations. These RSUs converted into common stock, and 581,718 shares were returned to the company to satisfy tax withholding obligations, with Burnell receiving the remaining shares. He also received a grant of 554,018 stock options with a strike price of $2.02 per share, vesting in four equal annual installments beginning August 20, 2027 and expiring August 20, 2036. Separately, 10,885 shares of common stock are reported as held indirectly by his spouse.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.
INTERPACE BIOSCIENCES, INC. (symbol: IDXG) is the issuer of record for a Form 4 filing submitted to the SEC.